Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal JPSCR : Journal of Pharmaceutical Science and Clinical Research Jurnal Farmasi Indonesia
Rahmita, Galuh Zhafirah
Unknown Affiliation
Environmental Science Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Tren Kepatuhan Pelaku Usaha Bidang Kosmetik di Indonesia Astuti, Sri; Wikara, Tina; Nurhayati, Sri; Sari, Evi Ratna; Carolina, Rotua Uli; Rahmita, Galuh Zhafirah
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol 18 No 2 (2026): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfionline.v18i2.741

Abstract

Compliance of business actors with regulations and standards such as the Good Manufacturing Practice (GMP) and regulations on the distribution, advertising and labelling of cosmetics is a crucial aspect in ensuring the safety and quality of cosmetic products to protect public health. This study aimed to assess the level of compliance of cosmetics business actors with regulations and standards in Indonesia. This quantitative study analyzed secondary data from the Indonesian FDA (BPOM)’s risk-based supervision of production and distribution facilities, advertising, and labelling across 34 provinces from 2019–2023. Each year, 4270–7,054 facilities were inspected and classified as compliant or non-compliant, and compliance proportions were calculated. The results were weighted using the Analytical Hierarchy Process (AHP) to produce a compliance index categorized into four levels: excellent (90.01–100), good (66.67–90), fair (33.34–66.66), and poor (0–33.33). The results of the analysis showed that the compliance index of cosmetics businesses for five years ranged from 71.62 to 83.79 and was classified as good: 82.79 (2019), 80.96 (2020), 75.41 (2021), 71.62 (2022), and 83.79 (2023). The index trend showed a fluctuating pattern from year to year, with the highest value recorded in 2023.
Adverse Drug Reactions, Treatment Adherence, and Treatment Outcomes in Drug-Resistant Tuberculosis Patients: A Single-center, Cross-sectional Study Syafhan, Nadia Farhanah; Rahmita, Galuh Zhafirah; Fitriani, Sri Wulandah
JPSCR: Journal of Pharmaceutical Science and Clinical Research Vol 10, No 2 (2025)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/jpscr.v10i2.87515

Abstract

Drug-Resistant Tuberculosis (DRTB) is a significant global health issue due to its rapid transmission and high morbidity. The variety of medications used in DRTB treatment increases the risk of adverse drug reactions (ADRs), which can contribute to patient nonadherence and adversely affect treatment outcomes. This study aimed to describe the occurrence of ADRs, quantify medication adherence rates, and assess treatment outcomes among patients with drugresistant tuberculosis (DRTB). Furthermore, it sought to analyse the associations between ADRs, demographic and clinical variables, medication adherence, and the associations between ADRs and treatment outcomes. Using a cross-sectional design, this study utilized medical records data and the Tuberculosis Information System (SITB) of adult DRTB patients treated at Universitas Indonesia Hospital from April 1, 2022, to February 28, 2023. A total sampling method was employed to select the research participants. Of the 65 patients, 60 (95.24%) experienced ADRs, and the Medication Refill Adherence method indicated an 89.23% adherence rate. Two patients (3.08%) were classified as successful or cured during the data collection period. Chi-square tests revealed no significant relationship between ADRs and medication adherence (p = 0.373) or treatment outcomes (p = 0.120). All demographic and clinical factors (age, gender, comorbidities, treatment combinations, and potential drug interactions) also showed no significant relationships with adherence (p > 0.05). In contrast, treatment combinations showed significant relationships with treatment outcomes (p = 0.013). These findings highlight the importance of medicines optimisation strategies, including proactive ADR management and adherence support, to improve treatment outcomes in DRTB patients.
Co-Authors Astuti, Sri Carolina, Rotua Uli Nadia Farhanah Syafhan Sari, Evi Ratna Sri Nurhayati Sri Wulandah Fitriani, Sri Wulandah Wikara, Tina